Cliff Asness's MLTX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 32,886 shares of MoonLake Immunotherapeutics (MLTX) worth $433,437, representing 0.00% of the portfolio. First purchased in 2023-Q4, this short-term holding has been held for 4 quarters.
Based on 13F filings, Cliff Asness has maintained this position in MLTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 32,886 shares. Largest reduction occurred in Q2 2024, reducing 5,858 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's MoonLake Immunotherapeutics (MLTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly MoonLake Immunotherapeutics (MLTX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +32,886 | New Buy | 32,886 | $13.18 |
| Q2 2024 | -5,858 | Sold Out | 0 | $0.00 |
| Q1 2024 | -630 | Reduce 9.71% | 5,858 | $50.23 |
| Q4 2023 | +6,488 | New Buy | 6,488 | $60.39 |
Cliff Asness's MoonLake Immunotherapeutics Investment FAQs
Cliff Asness first purchased MoonLake Immunotherapeutics (MLTX) in Q4 2023, acquiring 6,488 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held MoonLake Immunotherapeutics (MLTX) for 4 quarters since Q4 2023.
Cliff Asness's largest addition to MoonLake Immunotherapeutics (MLTX) was in Q4 2025, adding 32,886 shares worth $433,437.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 32,886 shares of MoonLake Immunotherapeutics (MLTX), valued at approximately $433,437.
As of the Q4 2025 filing, MoonLake Immunotherapeutics (MLTX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in MoonLake Immunotherapeutics (MLTX) was 32,886 shares, as reported at the end of Q4 2025.